Immuron (NASDAQ:IMRN – Get Free Report)’s share price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.16 and traded as low as $1.02. Immuron shares last traded at $1.0650, with a volume of 8,419 shares changing hands.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Immuron in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Read Our Latest Stock Report on Immuron
Immuron Stock Performance
Institutional Investors Weigh In On Immuron
An institutional investor recently bought a new stake in Immuron stock. Citadel Advisors LLC purchased a new position in Immuron (NASDAQ:IMRN – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned 0.29% of Immuron at the end of the most recent reporting period. Institutional investors and hedge funds own 0.12% of the company’s stock.
Immuron Company Profile
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.
Recommended Stories
- Five stocks we like better than Immuron
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Immuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron and related companies with MarketBeat.com's FREE daily email newsletter.
